

Regd. Office :  
1506, Chiranjiv Tower,  
43, Nehru Place, New Delhi-110019  
CIN No. : L74899DL1993PLC056594

Tel. : 011 - 47589500, 41608929  
Tel. : 011 - 21800032  
Fax : 011 - 26213081  
Web : www.medicamen.com

**Ref: STEX/RESULTS/2019-20**

**Date: 30<sup>th</sup> May, 2019**

**BSE Limited**  
Department of Corporate Services-Listing  
PJ Towers, Dalal Street  
Mumbai- 400001

**Company No.: 531146**

**Sub. : Outcome of Board Meeting.**

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today has inter alia:-

1. Approved the Audited Financial Statements of the Company for the financial year ended March 31, 2019 and the Audited Financial results for the quarter/year ended March 31, 2019, as recommended by the Audit Committee.
2. Recommended a Dividend of Rs. 1 per equity share of Rs. 10/-each for the financial year ended March 31, 2019.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- a) Statement showing the Audited Financial Results of the Company for the quarter/financial year ended March 31, 2019 as **Annexure-A** and
- b) Auditor's Report on the Audited Financial Results as **Annexure-B**.

Further Board of Directors at their meeting approved the following resolutions:

- c) Appointment of Dr Ravi Kumar Bansal (DIN: 08462513) as an Additional Director in an Independent category of the Company.

Please note that the reports of Auditors are with unmodified opinion with respect to the Audited Financial Results of the Company for the quarter/financial year ended March 31, 2019.


The meeting of the Board of Directors commenced on 11.30 a.m. and concluded at 01.20 p.m.


The Audited Financial Results of the Company for the quarter/financial year ended March 31, 2019, as approved by the Board, will also be available on the Company's website [www.medicamen.com](http://www.medicamen.com).

This is for your information and records.

Thanking You.

Yours faithfully,  
**For Medicamen Biotech Limited**

  
**Parul Choudhary**  
Company Secretary  
ACS-44157





# MEDICAMEN BIOTECH LIMITED

1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

## FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2019

### PART I

Rupees in Lacs (Except per Share data)


Particulars	Quarter Ended			Year Ended	
	3 Months Ended 31.03.2019	Preceding 3 Months Ended 31.12.2018	Corresponding 3 Months Ended 31.03.2018	31.03.2019	31.03.2018
	Audited	Unaudited	Audited	Audited	Audited
<b>1 Income from operations</b>					
(a) Net Sales / Income from operations (Net of GST)	3,327.04	2,408.25	2,930.08	12,260.45	11150.72
(b) Other Income	61.92	7.12	99.83	365.87	188.79
(c) <b>Total Revenue</b>	<b>3,388.96</b>	<b>2,415.37</b>	<b>3,029.91</b>	<b>12,626.32</b>	<b>11,339.51</b>
<b>2 Expenses</b>					
a) Cost of Material Consumed	2,383.86	1,629.24	1,864.82	7,996.44	6878.24
b) Purchase of Goods Traded	198.76	-	-	198.76	0.05
c) Changes in inventory of Finished Goods and Work in Progress	(45.96)	(184.09)	50.07	139.08	(113.07)
d) Employees Benefits Expenses	141.83	212.94	187.17	808.55	905.30
e) Finance Cost	2.56	20.33	51.05	93.77	240.81
f) Depreciation and Amortisation Expenses	66.04	59.24	49.88	221.40	205.79
g) Other expenses	220.14	312.12	449.80	1,397.12	1832.37
<b>Total Expenses</b>	<b>2,967.24</b>	<b>2,049.78</b>	<b>2,652.79</b>	<b>10,855.13</b>	<b>9,949.51</b>
<b>3 Profit/(Loss) before Exceptional Items &amp; Tax (1 - 2)</b>	<b>421.72</b>	<b>365.59</b>	<b>377.12</b>	<b>1,771.19</b>	<b>1,390.00</b>
<b>4 Exceptional Items (Commercial Tax Expenses Related to Earlier Years)</b>	-	-	-	-	-
<b>5 Profit/(Loss) before Extra Ordinary Items &amp; Taxn (3 - 4)</b>	<b>421.72</b>	<b>365.59</b>	<b>377.12</b>	<b>1,771.19</b>	<b>1,390.00</b>
<b>6 Tax Expenses</b>					
Current Year	123.39	132.83	195.26	549.63	401.78
Deferred Tax Liability	14.39	(7.69)	(4.38)	0.07	(23.05)
<b>Total Tax Expense</b>	<b>137.78</b>	<b>125.14</b>	<b>190.88</b>	<b>549.70</b>	<b>378.73</b>
<b>7 Net Profit /Loss for the period from Continuing operation (5- 6)</b>	<b>283.94</b>	<b>240.45</b>	<b>186.24</b>	<b>1,221.49</b>	<b>1,011.27</b>
<b>8 Other Comprehensive Income</b>					
Item that will not reclassified to Profit & Loss	-	-	-	-	-
<b>9 Total Comprehensive Income net of Tax</b>	<b>283.94</b>	<b>240.45</b>	<b>186.24</b>	<b>1,221.49</b>	<b>1,011.27</b>
<b>10 Paid up equity share capital (Rs. 10/- per share)</b>	<b>1,170.00</b>	<b>1,170.00</b>	<b>1,170.00</b>	<b>1,170.00</b>	<b>1170.00</b>
<b>11 Earning Per Share (Rs.)</b>					
Basic	2.43	2.06	1.66	10.44	9.03
Diluted	2.43	2.06	1.66	10.44	9.03

### NOTES :

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 30th, May, 2019.
- The figures are regrouped in previous year also, wherever considered necessary.
- The company operates only in one business segment , viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Ind AS-33
- Auditor's Report has been carried out by the Statutory Auditors for the above period.

For & on behalf of Board of Directors

Medicamen Biotech Limited

  
(Rahul Bishnoi)  
Chairman

Place : Delhi

Dated : 30.05.2019



STATEMENT OF ASSETS & LIABILITIES			
	Particulars	As at March 31, 2019 Audited	As at March 31, 2018 Audited
<b>A</b>	<b>ASSETS</b>		
1	<b>Non-current assets</b>		
	(a) Property, Plant and Equipment	2,404.67	2,501.87
	(b) Intangible assets	33.43	31.69
	(c) Capital work-in-progress	1,475.83	27.86
	(d) Financial Assets : Loans and advances	58.03	56.81
	(e) Other Non- current assets	70.45	38.26
	<b>Total Non-current Assets</b>	<b>4,042.41</b>	<b>2,656.48</b>
2	<b>Current assets</b>		
	(a) Inventories	1,526.03	1,423.42
	(b) Financial Assets		
	(i) Current investments	-	7.00
	(ii) Trade receivables	4,337.09	3,842.38
	(iii) Cash and Bank Balances	851.93	2,266.48
	(iv) Loans and advances	1,054.05	130.63
	(c) Other current assets	1,847.76	1,428.66
	<b>Total current Assets</b>	<b>9,616.85</b>	<b>9,098.57</b>
	<b>Total Assets</b>	<b>13,659.26</b>	<b>11,755.05</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
1	<b>Equity</b>		
	(a) Equity share capital	1,170.00	1,170.00
	(b) Other Equity	7,493.36	6,290.79
	<b>Total Equity</b>	<b>8,663.36</b>	<b>7,460.79</b>
	<b>LIBILITIES</b>		
2	<b>Non-current Liabilities</b>		
	(a) Financial Liabilities : Borrowings	2.09	14.18
	(b) Provisions	98.02	117.93
	(c) Deferred Tax liabilities (Net)	41.43	41.36
	<b>Total Non-current Liabilities</b>	<b>141.54</b>	<b>173.46</b>
3	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	1,161.33	1,424.45
	(ii) Trade payables	3,056.98	2,180.00
	(b) Other current liabilities	77.72	86.60
	(c) Provisions	558.33	429.76
		<b>4,854.36</b>	<b>4,120.80</b>
	<b>Total Equity and Liabilities</b>	<b>13,659.26</b>	<b>11,755.05</b>

For & on behalf of Board of Directors  
Medicamen Biotech Limited



*R. Bishnoi*

(Rahul Bishnoi)  
Chairman

Place : Delhi  
Dated : 30.05.2019



**TO THE BOARD OF DIRECTORS OF  
Medicamen Biotech Limited**

1. We have audited the accompanying Statement of Standalone Financial Results of Medicamen Biotech Limited ("the Company") for the year ended March 31, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement, which is the responsibility of the Company's Management and approved by the Parent's Board of Directors, has been compiled from the related Standalone financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such standalone financial statements.
3. We conducted our audit in accordance with the Standards on Auditing issued by institute of Chartered Accountants. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.
4. An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the Company's internal control with reference to the Statement. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion

5. In our opinion and to the best of our information and according to the explanations given to us the Statement:
  - i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
  - ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net



income and total comprehensive income and other financial information of the Company for the year ended March 31, 2019.

4. The Statement includes the results for the quarter ended March 31, 2019 being the balancing figure between audited figures in respect of the full financial year and the published audited year to date figures up to the third quarter of the current financial year.

Our opinion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done.

For Rai Qimat & Associates  
Chartered Accountants



Qimat Rai Garg  
Partner  
(Membership Number: 013152C)

Place: New Delhi  
Date: 30.05.2019